CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients by Lesche, Dorothea et al.
ORIGINAL ARTICLE
CYP3A5*3 and POR*28 Genetic Variants Influence the
Required Dose of Tacrolimus in Heart Transplant Recipients
Dorothea Lesche, MSc,*† Vilborg Sigurdardottir, MD, PhD,‡ Raschid Setoud, PhD,‡
Markus Oberhänsli, MD,‡ Thierry Carrel, MD,§ Georg M. Fiedler, MD,* Carlo R. Largiadèr, PhD,*
Paul Mohacsi, Prof,‡ and Johanna Sistonen, PhD*
Background: After heart transplantation (HTx), the interindividual
pharmacokinetic variability of immunosuppressive drugs represents
a major therapeutic challenge due to the narrow therapeutic window
between over-immunosuppression causing toxicity and under-
immunosuppression leading to graft rejection. Although genetic poly-
morphisms have been shown to inﬂuence pharmacokinetics of immu-
nosuppressants, data in the context of HTx are scarce. We thus assessed
the role of genetic variation in CYP3A4, CYP3A5, POR, NR1I2, and
ABCB1 acting jointly in immunosuppressive drug pathways in tacroli-
mus (TAC) and ciclosporin (CSA) dose requirement in HTx recipients.
Methods: Associations between 7 functional genetic variants and
blood dose-adjusted trough (C0) concentrations of TAC and CSA at
1, 3, 6, and 12 months after HTx were evaluated in cohorts of 52 and
45 patients, respectively.
Results: Compared with CYP3A5 nonexpressors (*3/*3 genotype),
CYP3A5 expressors (*1/*3 or *1/*1 genotype) required around 2.2-
to 2.6-fold higher daily TAC doses to reach the targeted C0 concen-
tration at all studied time points (P # 0.003). Additionally, the
POR*28 variant carriers showed higher dose-adjusted TAC-C0 con-
centrations at all time points resulting in signiﬁcant differences at 3
(P = 0.025) and 6 months (P = 0.047) after HTx. No signiﬁcant
associations were observed between the genetic variants and the
CSA dose requirement.
Conclusions: The CYP3A5*3 variant has a major inﬂuence on
the required TAC dose in HTx recipients, whereas the POR*28
may additionally contribute to the observed variability. These results
support the importance of genetic markers in TAC dose optimization
after HTx.
Key Words: heart transplantation, tacrolimus, ciclosporin, pharma-
cogenomics
(Ther Drug Monit 2014;36:710–715)
INTRODUCTION
Immunosuppressive drug therapy after organ trans-
plantation is complicated by the narrow therapeutic window
of the drugs combined with high and unpredictable interin-
dividual variability in response to standard administered
doses. It has been increasingly recognized that, along with
factors like kidney function and drug interactions, genetic
variation contributes to this large variability in response.1–3
Although genetic factors inﬂuencing immunosuppressive
response have been more widely studied in kidney and liver
transplant patients, data in the context of heart transplantation
(HTx) are scarce. Because management of HTx recipients has
unique characteristics, such as higher level of required immu-
nosuppression combined with risk of serious toxic complica-
tions or graft failure, studies focusing speciﬁcally on this
patient population are clinically important. Furthermore, the
effect of a patient’s genetic variation on drug pharmacokinet-
ics may differ between heart and other solid organ transplants,
such as the kidneys and the liver, where donor genetic vari-
ation could also affect drug metabolism and elimination.
Calcineurin inhibitors (CNIs) are currently still the basis
of immunosuppressive protocols after HTx.4 Drug-metabolizing
enzymes cytochrome P450 (CYP) 3A4 and CYP3A5 and the
efﬂux transporter P-glycoprotein [ATP-binding cassette B1
(ABCB1)], which are responsible for the ﬁrst-pass metabolism
and systemic clearance of CNIs, are the major determinants of
their pharmacokinetics.5 The majority of the previous studies
have focused on the common CYP3A5*3 (rs776746) variant,
which results in a cryptic splice site and nonfunctional CYP3A5
protein. CYP3A5 expressors (ie, carriers of *1/*1 or *1/*3
genotype) have been shown to require higher daily dose of
both tacrolimus (TAC) and ciclosporin (CSA) to reach the
targeted blood trough (C0) concentrations compared with
CYP3A5 nonexpressors (*3/*3).6–8 Additionally, polymor-
phisms in the ABCB1 gene have been widely studied but
with controversial results.7,9–11
Recently, a novel functional polymorphism in CYP3A4
(CYP3A4*22; rs35599367) was described and associated with
lower CNI dose requirement in transplant patients.12–15 Fur-
thermore, polymorphisms in the P450 oxidoreductase (POR
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gene) and pregnane X receptor (PXR, NR1I2 gene) have been
shown to modulate the activity of CYP3A enzymes and to
alter the pharmacokinetics of TAC in kidney transplant pa-
tients.16,17 Studying multiple polymorphisms in genes acting
together on an immunosuppressive drug pathway instead of
single variants may provide new insight into factors inﬂuenc-
ing the response.18
In this study, our main aim was to evaluate the effect of
functional polymorphisms in 5 candidate genes on TAC and
CSA dose requirement during the ﬁrst year after transplanta-
tion. Because altered drug pharmacokinetics may inﬂuence the
treatment efﬁcacy and toxicity, we additionally explored the
potential role of genetic variation in the treatment outcome in
terms of allograft rejection and renal function.
MATERIALS AND METHODS
Study Population
This study was a retrospective observational cohort
study including HTx recipients from the University Hospital
Bern (Inselspital), who underwent transplantation between the
years 1994 and 2012 and were alive in April 2012. All
consecutive patients were invited to participate in the study
during their regular follow-up visits, except patients fulﬁlling
the exclusion criteria (ie, patients having received more than 1
transplant or being younger than 16 years). All transplant
recipients received perioperative immunosuppressive therapy
with 5 mg/kg of azathioprine (AZA) and 1000 mg of
methylprednisolone. Antithymocyte globulin (4–5 mg/kg)
was initiated within 12 hours posttransplant and continued
for up to a maximum of 5 days tailored by CD3 cell count.
All patients received a CNI for early postoperative immuno-
suppression and for maintenance treatment in combination
with prednisone (0.8 mg$kg21$d21 tapered to 0.15
mg$kg21$d21 within 5 months) and AZA or mycophenolate
mofetil (replaced AZA in 2007). In case of severe early post-
operative kidney dysfunction, CNI was tapered or replaced by
a mammalian target of rapamycin (mTOR) inhibitor. The
targeted C0 concentration was 170–220 ng/mL (or 50–75
ng/mL in case of the combination with an mTOR inhibitor)
for CSA and 8–14 ng/mL (or 3–5 ng/mL in case of the
combination with an mTOR inhibitor) for TAC. The targeted
C0 concentrations for the mTOR inhibitors everolimus and
sirolimus were 6–8 and 10–12 ng/mL, respectively. Protocol
endomyocardial biopsy specimens were performed weekly
during the ﬁrst postoperative month. Thereafter, the intervals
were extended depending on the individual clinical course.
The endomyocardial biopsy results were classiﬁed according
to the guidelines of the International Society of Heart and
Lung Transplantation.19 Renal function was assessed by an
estimate of the glomerular ﬁltration rate (eGFR) calculated by
the Chronic Kidney Disease Epidemiology Collaboration
equation.20 EDTA blood samples for genetic analyses were
collected at the time of study recruitment. Clinical data,
including patient characteristics, dosing and blood C0 concen-
trations of TAC and CSA, concomitant drug therapy (such as
statins, calcium channel blockers, antibiotics, and antimy-
cotics), and number of clinically relevant (grade $ 2R)
biopsy-proven allograft rejections at 1, 3, 6, and 12 months
post-HTx, were retrieved from the patient charts. Patients’
immunosuppressive therapy regimen at 1 month after HTx
was used to assign patients into TAC and CSA treatment
groups. All patients received an oral and a written description
of the study protocol and signed a written informed consent.
The study was approved by the Cantonal Ethics Committee of
Bern (KEK 031/12).
Dose-Adjusted Drug C0 Concentrations
Blood concentration measurements of TAC and CSA
were obtained from the routine therapeutic drug monitoring.
The C0 concentrations were measured in whole blood sam-
ples using chemiluminescence microparticle immunoassays
on the Architect i2000SRTM (Abbott Laboratories, Abbott
Park, IL) since 2008. A microparticle immunoassay on the
Abbott IMX was previously used for TAC and a chemilumi-
nescence microparticle immunoassay for CSA on the same
platform. Dose-adjusted drug C0 concentration was used as an
outcome variable, as commonly done in other stud-
ies,7,8,11,13,21,22 and deﬁned as drug C0 concentration per daily
weight-adjusted drug dose [(ng/mL)/(mg$kg21$d21)].
Selection of Genetic Variants and Genotyping
Genetic variants were selected based on previous
literature. Seven candidate polymorphisms in 5 genes shown
to inﬂuence the metabolism or transport of TAC and/or CSA
were selected. These included variants in drug-metabolizing
enzymes: CYP3A5*3 (rs776746) and CYP3A4*22
(rs35599367)13; in proteins modifying the CYP enzyme activ-
ity: POR*28 (rs1057868)17 and NR1I2 -25385C.T
(rs3814055)16; and in the efﬂux transporter P-glycoprotein:
ABCB1 c.1236C.T (rs1128503), c.2677G.T/A
(rs2032582), and c.3435C.T (rs1045642).7,9,11
Genomic DNA was extracted from EDTA blood
samples using QIAamp DNA Blood Midi Kit (Qiagen AG,
Basel, Switzerland). Genetic variants were genotyped using
TaqMan SNP and Drug Metabolism Genotyping Assays
(Applied Biosystems, Foster City, CA): C_59013445_10 for
CYP3A4*22, C_26201809_30 for CYP3A5*3,
C_8890131_30 for POR*28, C_27504984_30 for NR1I2
-25385C.T, C_7586662_10 for ABCB1 c.1236C.T,
C_11711720C_30 and C_11711720D_40 for c.2677G.T/
A, and C_7586657_20 for c.3435C.T. Allelic discrimination
was performed on a 7500 Fast Real-Time PCR System
(Applied Biosystems) according to the manufacturer’s proto-
col. Genotyping results of 21 patient samples representing
different genotypes of the studied polymorphisms were con-
ﬁrmed by Sanger sequencing.
Statistical Analyses
Statistical analyses were performed using the Predictive
Analytics Software statistics for Windows version 21.0
(SPSS, Inc, Chicago, IL) unless otherwise stated. Normal
distribution of data was assessed by Kolmogorov–Smirnov
test and data were presented as mean (6 SD) or as median
(interquartile range) where appropriate. The dose-adjusted
TAC-C0 and CSA-C0 concentrations were normalized by
logarithmic transformation. Genotype frequencies of the
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polymorphisms were tested for deviations from Hardy–Wein-
berg equilibrium using exact tests implemented in the software
Arlequin v.3.5.1.3.23 Pairwise linkage disequilibrium between
ABCB1 polymorphisms was assessed by calculating the
D0 coefﬁcient24 and tested as implemented in the package
“genetics” in the R software (http://www.r-project.org).
ABCB1 haplotypes were inferred for the 3 loci (showing
D0 $ 0.89; P , 0.001) using the Excofﬁer–Laval–Balding algo-
rithm implemented in Arlequin.25 The associations of genetic
variants with dose-adjusted TAC-C0 and CSA-C0 concentrations
were evaluated at 1, 3, 6, and 12 months after HTx using linear
regression analysis adjusted for clinical factors, namely, age, sex,
eGFR, daily prednisone dose, and calcium channel blocker use.
The information on the use of other drugs inhibiting (ie, ﬂucona-
zole, voriconazole) or inducing (ie, rifampin) CYP3A enzymes
was omitted from the analysis because only single patients
received these drugs at the studied time points. An additive model
was assumed for all genetic variants. Percentage change in the
untransformed dose-adjusted C0 concentration was determined by
back-transforming estimated regression coefﬁcients using equa-
tion ½ðeb21Þ · 100. The Mann–Whitney U test was used
for pairwise comparisons of continuous variables and the Fisher
exact test for comparisons of categorical variables. Repeated-
measures analysis of variance was used to compare the eGFR
values between genotype groups during the ﬁrst year post-HTx.
Two-sided nominal P values, 0.05 were considered statistically
signiﬁcant. No correction for multiple testing was performed
because of the exploratory nature of this study.
RESULTS
The study population consisted of 104 HTx recipients
(78 males) with a mean age of 47.4 years, the majority
being whites (95%) (Table 1). The mean posttransplant
follow-up time was 7.6 (64.9) years. At 1 month after
HTx, immunosuppressive therapy regimen was based on
TAC for 52 patients and on CSA for 45 patients. Seven
patients on a CNI-free therapy regimen (Table 1) were
excluded from further data analyses. The genotype frequen-
cies of the studied polymorphisms (Table 2) were in accor-
dance with Hardy–Weinberg equilibrium (P . 0.05), and
the observed allele frequencies were similar to the previ-
ously described frequencies in whites.26
Associations of Genetic Variants With
Dose-Adjusted Drug-C0 Concentrations
The CYP3A5*3 variant was strongly associated with the
dose-adjusted TAC-C0 concentration during the ﬁrst year
after HTx (Table 3).27 CYP3A5 expressors had lower dose-
adjusted TAC-C0 concentrations at all studied time points
(P # 0.002; Fig. 1; Table 4) and required 2.2- to 2.6-fold
higher drug dose to reach the targeted concentration com-
pared with CYP3A5 nonexpressors (Table 4). Additionally,
the POR*28 variant carriers showed higher dose-adjusted
TAC-C0 concentrations at all time points resulting in signif-
icant differences at 3 (P = 0.025) and 6 months (P = 0.047)
after HTx (Table 3). In contrast to TAC, no consistent asso-
ciations between the genetic variants and the dose-adjusted
CSA-C0 concentration during the ﬁrst year of therapy were
observed (see Table, Supplemental Digital Content 1,
http://links.lww.com/TDM/A89).
Relationship Between CYP3A5*3 Genotype
and TAC Treatment Outcome
As a strong effect of the CYP3A5*3 variant on the
required TAC dose to reach the targeted C0 concentration
was observed, its impact on the treatment outcome in terms
of allograft rejection and renal function during the ﬁrst year
after HTx was evaluated. Although no signiﬁcant differences
in the incidence of clinically relevant biopsy-proven allograft
rejection in relation to the CYP3A5*3 genotype were
observed, the number of patients experiencing early allograft
rejection (ie, within the ﬁrst 3 months after HTx) was higher
among CYP3A5 expressors 46% (6/13) compared with non-
expressors 28% (11/39) (P = 0.31). The eGFR decreased in
the TAC treatment cohort from 75.9 (635.3) mL/min/1.73 m2
at 1 month to 64.9 (627.8) mL/min/1.73 m2 at 12 months
after HTx. CYP3A5*3 genotype had no inﬂuence on the
development of the eGFR values (P = 0.68).
DISCUSSION
Although substantial variability exists in the immuno-
suppressive response of heart transplant patients, predictive
markers to optimize the therapy in the early postoperative
TABLE 1. Baseline Characteristics of the Study Population
(n = 104)
Variable
Male sex, n (%) 78 (75)
Age at the time of transplant (yrs) 47.4 (614.3)
Weight at the time of transplant (kg) 70.7 (614.1)
Ethnicity, n (%)
White 99 (95)
Asian 3 (3)
Other 2 (2)
Primary cause of transplantation, n (%)
Dilated cardiomyopathy 46 (44)
Coronary artery disease 39 (38)
Other 19 (18)
eGFR before transplantation (mL/min/1.73 m2) 73.5 (631.2)
Drug therapy at 1 mo after transplantation, n (%)
Statins* 80 (77)
Prednisone (mg$kg21$d21) 0.37 (0.32–0.46)
CSA + MMF or AZA 43 (41)
CSA + SRL 2 (2)
TAC 1 (1)
TAC + MMF or AZA 46 (44)
TAC + SRL 1 (1)
TAC + ERL + MMF 4 (4)
ERL + MMF 7 (7)
Continuous data are presented as mean (6SD) or as median (interquartile range)
where appropriate.
*The use of statins gradually increased: at 12 months after transplantation 93 (89%)
patients were on statin therapy.
ERL, everolimus; MMF, mycophenolate mofetil; SRL, sirolimus.
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phase are currently lacking. In this study, we assessed the role
of 7 genetic variants in 5 candidate genes acting jointly in the
metabolism and transport pathways of immunosuppressants
in the dose requirement of TAC and CSA in a cohort of 104
HTx recipients. Our main results suggest that the CYP3A5*3
variant has a major inﬂuence on the required TAC dose in
HTx recipients, whereas the POR*28 may additionally con-
tribute to the observed variability.
Our results showed that the CYP3A5 expressors had
signiﬁcantly lower dose-adjusted TAC-C0 concentrations
compared with CYP3A5 nonexpressors at all studied time
points requiring around 2.2- to 2.6-fold higher daily TAC
doses to reach the targeted blood C0 concentration. A similar
effect of the CYP3A5*3 variant on TAC dose requirement has
been shown also in the previous studies on HTx recipients,
based on cohorts of 15 and 65 adult patients21,28 and 37 and
54 pediatric patients.11,22 This study, however, was the ﬁrst to
investigate the inﬂuence of the POR*28 variant on TAC and
CSA dose requirement in HTx recipients.
POR is a modulator of CYP enzyme activity. It is
a microsomal ﬂavoprotein that transfers electrons from
NADPH to CYP enzymes, enabling their catalytic activity.29
Of known polymorphisms in the POR gene, the POR*28
variant, which induces an amino acid substitution A503V,
has been the most widely investigated.30 Although in vitro
studies have shown that this variant leads to decreased cata-
lytic activity, the effect in vivo seems to vary depending
on the enzyme and substrate analyzed.31 De Jonge et al17
reported in their study on 298 de novo kidney transplant
recipients a signiﬁcantly higher TAC dose requirement in
carriers of the POR*28 during the ﬁrst year of therapy but
only if they were CYP3A5 expressors (n = 52). Similarly,
a lower TAC exposure in carriers of the POR*28 was
described exclusively in CYP3A5 expressors in a recent study
on 43 pediatric kidney transplant recipients32 and in a phar-
macokinetic study on 71 healthy Chinese male volunteers
receiving a single oral TAC dose of 2 mg.33 Our results
showing signiﬁcantly higher dose-adjusted TAC-C0 concen-
trations in carriers of the POR*28, which indicates a lower
TAC dose requirement in these patients, are thus in line with
the previous in vitro data but in contrast to the in vivo studies
on TAC exposure. Subanalysis of the POR*28 in different
CYP3A5*3 genotype groups was not meaningful in our TAC
study cohort including only 13 CYP3A5 expressors of whom
4 carried the POR*28 variant. Larger HTx patient cohorts
TABLE 2. Genotype Frequencies
Genotype
TAC Treatment Group CSA Treatment Group
(n = 52), n (%) (n = 45), n (%)
CYP3A4*22
*1/*1 51 (98) 39 (87)
*1/*22 1 (2) 6 (13)
*22/*22 0 (0) 0 (0)
CYP3A5*3
*1/*1 1 (2) 0 (0)
*1/*3 12 (23) 9 (20)
*3/*3 39 (75) 36 (80)
POR*28
*1/*1 27 (52) 22 (49)
*1/*28 18 (35) 19 (42)
*28/*28 7 (13) 4 (9)
NR1I2 -25385C.T
C/C 22 (42) 17 (38)
C/T 26 (50) 19 (42)
T/T 4 (8) 9 (20)
ABCB1 c.1236C.T
C/C 19 (37) 14 (31)
C/T 21 (40) 22 (49)
T/T 12 (23) 9 (20)
ABCB1 c.2677G.T/A
G/G 15 (29) 11 (24)
G/A 3 (6) 3 (7)
G/T 21 (40) 23 (51)
T/A 1 (2) 0 (0)
T/T 12 (23) 8 (18)
ABCB1 c.3435C.T
C/C 13 (25) 10 (22)
C/T 22 (42) 20 (45)
T/T 17 (33) 15 (33)
*1 indicates wild type (see http://www.cypalleles.ki.se/).
TABLE 3. Associations of Genetic Variants and Normalized TAC Dose-Adjusted C0 Concentrations
Genetic Variant Time After Transplantation
1 mo (n = 51)* 3 mo (n = 47)* 6 mo (n = 46) 12 mo (n = 40)*
Best (%) R2 P Best (%) R2 P Best (%) R2 P Best (%) R2 P
CYP3A5*3 65 0.33 0.002 133 0.57 ,0.001 134 0.50 ,0.001 220 0.57 ,0.001
POR*28 9 0.17 0.47 35 0.33 0.025 28 0.29 0.047 25 0.18 0.22
NR1I2 -25385C.T 27 0.22 0.08 23 0.24 0.84 21 0.20 0.97 223 0.17 0.26
ABCB1 c.1236C.T† 211 0.18 0.31 24 0.24 0.73 24 0.21 0.73 23 0.14 0.85
ABCB1 c.2677G.T/A† 28 0.17 0.47 23 0.24 0.80 1 0.21 0.92 0 0.14 0.98
ABCB1 c.3435C.T† 27 0.17 0.55 6 0.24 0.67 9 0.22 0.46 8 0.14 0.60
Linear regression analysis of each genetic variant was performed using an additive genetic model and adjusted for age, sex, eGFR, prednisone dose, and calcium
channel blocker use. Bold font indicates P , 0.05.
*TAC dose-adjusted C0 concentration was missing for 1 patient at 1, 3, and 12 months after HTx.
†Rare ABCB1 c.2677A allele was grouped with the wild-type G allele in the analysis based on its predicted functional effect.27 ABCB1 polymorphisms were also analyzed on
a haplotype level but no signiﬁcant associations were observed.
Best, estimated percentage change in the outcome variable; R2, coefﬁcient of determination of full model.
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are needed to further elucidate the effect of this polymor-
phism, in combination with CYP genetic variants, on TAC
pharmacokinetics.
In contrast to TAC, no consistent associations between
the genetic variants and the CSA dose requirement were
observed. Previous studies on the effect of the CYP3A5*3
variant on CSA dose requirement have yielded controversial
results. A meta-analysis by Zhu et al8 based on 1742 kidney
transplant patients showed a signiﬁcant association between
CYP3A5 nonexpressors and higher dose-adjusted CSA-C0
concentration, indicative of lower dose requirement in these
patients compared with CYP3A5 expressors. However, no
effect or an opposite effect has also been reported.34–36 Based
on a statistical power analysis, this study including 45 patients
on a CSA-based therapy could detect a 35% change in the dose-
adjusted CSA-C0 concentration between CYP3A5 expressors
and nonexpressors with a power of 80% at an alpha level of
0.05. Therefore, although our results do not rule out an effect of
CYP3A5*3 genotype on CSA dose requirement, it is not a strong
predictor as in the case of TAC.
Because of the relatively small patient cohort, this study
was statistically underpowered to detect even large differ-
ences in clinical outcomes between CYP3A5 expressors and
nonexpressors. However, it is worth noting that a higher
number of CYP3A5 expressors (46%) experienced early
allograft rejection in our TAC patient cohort compared with
CYP3A5 nonexpressors (28%) (P = 0.31). This is in agree-
ment with Tang et al6 who reported in their meta-analysis
including 1779 kidney and liver transplant patients on
TAC-based therapy signiﬁcantly higher rate of acute graft
rejections in CYP3A5 expressors compared with nonexpres-
sors over the ﬁrst month after transplantation (odds ratio,
3.27; 95% CI, 1.57–6.81; P = 0.002). The inﬂuence of higher
daily TAC dose requirement and potentially longer dose-
adjustment time in CYP3A5 expressors on the risk of allo-
graft rejection during the ﬁrst months after HTx needs further
evaluation.
The limitations of our study include a small cohort of
patients who underwent transplantation during a period of 18
years. Changes in surgical techniques and clinical protocols
within this time may have inﬂuenced the treatment outcomes
in these patients. Clinical data, such as drug C0 concentra-
tions, were retrospectively retrieved from the patient charts
introducing potential errors to the data. However, we expect
that these limitations are independent of a patient’s genotype
and thus should rather lead to an underestimation of the asso-
ciations between the pharmacokinetics of immunosuppressants
TABLE 4. TAC Dose and C0 Concentration in CYP3A5 Expressors and Nonexpressors
CYP3A5 Expressors n* CYP3A5 Nonexpressors n* P
Dose (mg$kg21$d21)
1 mo 0.24 (0.16–0.35) 11 0.11 (0.09–0.17) 35 0.003
3 mo 0.22 (0.17–0.28) 8 0.09 (0.06–0.13) 32 ,0.001
6 mo 0.21 (0.16–0.23) 6 0.08 (0.06–0.11) 34 ,0.001
12 mo 0.16 (0.11–0.18) 6 0.07 (0.05–0.09) 29 ,0.001
C0 (ng/mL)
1 mo 13.4 (10.4–15.4) 11 12.8 (11.5–15.9) 35 0.51
3 mo 10.6 (10.0–13.0) 8 12.6 (11.2–14.1) 32 0.15
6 mo 13.9 (11.8–14.9) 6 11.8 (10.2–13.5) 34 0.12
12 mo 9.5 (7.9–12.8) 6 12.6 (11.2–15.5) 29 0.07
Dose-adjusted C0 [(ng/mL)/
(mg$kg21$d21)]
1 mo 61.2 (43.0–71.9) 11 122.2 (85.2–154.0) 35 0.001
3 mo 43.1 (37.9–77.7) 8 139.1 (116.1–186.8) 32 ,0.001
6 mo 61.1 (54.1–93.0) 6 149.3 (114.8–205.4) 34 ,0.001
12 mo 64.8 (49.9–84.1) 6 206.3 (141.0–245.3) 29 ,0.001
Data are presented as median (interquartile range). Bold font indicates P , 0.05.
*Small number of patients on a combination therapy with an mTOR inhibitor were excluded from the analysis because of different target C0 concentration.
FIGURE 1. Dose-adjusted TAC-C0 concentrations in blood
during 1 year after transplantation in CYP3A5 expressors
(*1/*1 or *1/*3 genotype) and nonexpressors (*3/*3). The
horizontal line represents the median value. The difference
between CYP3A5 expressors and nonexpressors was sig-
nificant at each time point (P # 0.001).
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and genetic factors. Finally, the number of studied genetic
variants was limited, and thus, important genetic effects may
have remained undetected in this study.
CONCLUSIONS
We have shown that the CYP3A5*3 variant has a major
inﬂuence on the required TAC dose in HTx recipients.
Because this ﬁnding is supported by other studies on HTx
recipients, adjusting the starting dose of TAC based on the
CYP3A5*3 genotype would require evaluation in a multi-
centre prospective study. The POR*28 variant was addition-
ally identiﬁed in our study as a new candidate marker
inﬂuencing TAC pharmacokinetics in HTx recipients. Our
results support the importance of genetic markers in TAC
dose optimization after HTx.
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